GlassScriptPhysician profile
Traci B Johns
NPI 1427315845
$2,310.81
in general payments reported to CMS, 2019-2025
29 companies · $636 in 2025
The $636 reported for 2025 was more than what 78% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $559 · 2022: $420 · 2023: $289 · 2024: $406 · 2025: $636.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,308 · Education: $23.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,308.09 |
| Education | $23.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $412.77 | 2021-2025 | Erleada |
| Bayer Healthcare Pharmaceuticals INC. | $225.43 | 2021-2025 | |
| Astellas Pharma US INC | $214.23 | 2021-2024 | Xtandi |
| Pfizer INC. | $164.35 | 2021-2025 | |
| Sumitomo Pharma America, INC. | $145.63 | 2023-2025 | Orgovyx, Gemtesa |
| Boston Scientific Corporation | $130.99 | 2021-2025 | Lithovue, General - Kidney Stone Disease |
| Dendreon Pharmaceuticals LLC | $118.02 | 2023-2025 | Provenge |
| Myriad Genetic Laboratories, INC. | $115.42 | 2022-2025 | Prolaris, Myrisk |
| Abbvie INC. | $111.71 | 2021-2024 | |
| Ferring Pharmaceuticals INC. | $80.66 | 2024-2025 | Adstiladrin |
| Endo USA, INC. | $67.71 | 2024-2025 | Xiaflex, Aveed |
| Verity Pharmaceuticals INC. | $54.21 | 2025 | Trelstar |
| Tolmar, INC. | $53.38 | 2023 | |
| Coloplast Corp | $52.55 | 2022-2025 | |
| Amgen INC. | $49.57 | 2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rochester Medical Corporation | $46.61 | 2021 | |
| Angiodynamics, INC. | $33.82 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $33.80 | 2021-2022 | |
| Urovant Sciences INC | $25.71 | 2021 | |
| C. R. Bard, INC. & Subsidiaries | $23.76 | 2025 | Bard Urinary Drainage Bag |
| Procept Biorobotics Corporation | $23.60 | 2025 | |
| Urogen Pharma, INC. | $20.50 | 2022 | |
| Novartis Pharmaceuticals Corporation | $18.97 | 2025 | |
| Endo Pharmaceuticals INC. | $18.12 | 2022 | |
| Myovant Sciences INC. | $18.07 | 2021 | |
| Dentsply Ih Ab | $17.18 | 2025 | Lofric |
| Olympus America INC. | $15.39 | 2025 | Itind System |
| Abbott Laboratories | $12.39 | 2021 | |
| Ambu INC. | $6.26 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Traci Johns listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.